


## Enbezotinib

Cat. No.:	HY-145565		
CAS No.:	2359649-81-1		
Molecular Formula:	C <sub>21</sub> H <sub>21</sub> FN <sub>6</sub> O <sub>3</sub>		
Molecular Weight:	424.43		
Target:	RET		
Pathway:	Protein Tyrosine Kinase/RTK		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (235.61 mM; ultrasonic and warming and heat to 80°C)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.3561 mL	11.7805 mL	23.5610 mL
		5 mM	0.4712 mL	2.3561 mL	4.7122 mL
10 mM		0.2356 mL	1.1781 mL	2.3561 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.90 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.90 mM); Clear solution				

### BIOLOGICAL ACTIVITY

Description	Enbezotinib, an inhibitor of RET, can inhibit the RET autophosphorylation. Enbezotinib can be used for the research of cancer <sup>[1]</sup> .
IC <sub>50</sub> & Target	RET <sup>[1]</sup>
In Vitro	Enbezotinib (compound 5) (0.3-300 nM) inhibits p-RET (y905) in RET-driven cells <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Enbezotinib (compound 5) (2-5 mg/kg; twice daily for 27 days) decreases tumor size in mice <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

[1]. ROGERS EW, et, al. Macrocyclic compounds for treating disease. WO2019126121A1.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA